Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

21 Aug 2021

Abstract excerpt

A wide range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing monoclonal antibodies (mAbs) have been reported, most of which target the spike glycoprotein. Therapeutic implementation of these antibodies has been challenged by emerging SARS-CoV-2 variants harboring mutated spike versions. Consequently, re-assessment of previously identified mAbs is of high priority. Four previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34464610
DOI: 10.1016/j.celrep.2021.109679

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsPMID 34464610Read ↗

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variantsSemantic proximity Read ↗

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainSemantic proximity Read ↗

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.Semantic proximity Read ↗

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 miceSemantic proximity Read ↗

Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.Semantic proximity Read ↗

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsSemantic proximity Read ↗

Cross-Neutralizing Monoclonal Antibodies with Broad Activity Against Human and Bat-Derived SARS-Related CoronavirusesSemantic proximity Read ↗

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibodySemantic proximity Read ↗

Broadly neutralizing antibodies against COVID-19Semantic proximity Read ↗

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strainsSemantic proximity Read ↗

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeSemantic proximity Read ↗

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.